Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study) : a randomised, double-blind, parallel-group trial. Commentary
Identifieur interne : 000725 ( PascalFrancis/Curation ); précédent : 000724; suivant : 000726Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study) : a randomised, double-blind, parallel-group trial. Commentary
Auteurs : Carl E. Clarke [Royaume-Uni] ; O. Rascol [France] ; D. J. Brooks [Royaume-Uni] ; E. Melamed [Israël] ; W. Oertel [Allemagne] ; W. Poewe [Autriche] ; F. Stocchi [Italie] ; E. Tolosa [Espagne]Source :
- Lancet : (British edition) [ 0140-6736 ] ; 2005.
Descripteurs français
- Pascal (Inist)
- Wicri :
English descriptors
- KwdEn :
Abstract
Background Rasagiline mesylate is a novel drug for Parkinson's disease with selective, irreversible monoamine oxidase B (MAO-B) inhibitor activity, and is effective as monotherapy in early disease. This study investigated rasagiline efficacy and safety in levodopa-treated patients with Parkinson's disease and motor fluctuations. Methods In an 18-week, double-blind, multicentre (74 hospitals and academic centres in Israel, Argentina, and Europe) trial, 687 outpatients were randomly assigned to oral rasagiline (231 individuals; 1 mg once daily), entacapone (227; 200 mg with every levodopa dose), or placebo (229). Primary outcome was change in total daily off-time (intention-to-treat population). Other measures included the clinical global improvement (CGI) score and unified Parkinson's disease rating scale (UPDRS) scores. Analysis was by intention to treat. Findings 88 (13%) patients who were assigned treatment did not complete the study (23 rasagiline, 30 entacapone, 35 placebo), mainly because of withdrawal of consent (n=34) and adverse events (n=34). Both rasagiline and entacapone reduced mean daily off-time (-1.18 h rasagiline and -1.2 h entacapone vs placebo -0.4 h; p=0.0001, p<0.0001, respectively) and increased daily on-time without troublesome dyskinesia (0.85 h vs placebo 0.03 h; p=0.0005 for both). We recorded significant mean improvements in CGI scores (-0.86 rasagiline and -0.72 entacapone vs -0.37 placebo; p<0.0001, p=0.0002, respectively). Changes in UPDRS scores also significantly improved for activities of daily living during off-time (-1.71 and -1.38 vs placebo; p<0.0001, p=0.0006, respectively) and motor function during on-time (-2.94 and -2.73 vs placebo; both p<0.0001). Frequency of adverse events was similar for all treatments. Interpretation Once-daily rasagiline reduces mean daily off-time and improves symptoms of Parkinson's disease in levodopa-treated patients with motor fluctuations, an effect similar to that of entacapone.
| pA |
|
|---|
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000D09
Links to Exploration step
Pascal:05-0151757Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study) : a randomised, double-blind, parallel-group trial. Commentary</title><author><name sortKey="Clarke, Carl E" sort="Clarke, Carl E" uniqKey="Clarke C" first="Carl E." last="Clarke">Carl E. Clarke</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>University of Birmingham and Department of Neurology, City Hospital</s1><s2>Birmingham B18 7QH</s2><s3>GBR</s3><sZ>1 aut.</sZ></inist:fA14><country>Royaume-Uni</country></affiliation></author><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O." last="Rascol">O. Rascol</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Clinical Pharmacology, University Hospital</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>2 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Brooks, D J" sort="Brooks, D J" uniqKey="Brooks D" first="D. J." last="Brooks">D. J. Brooks</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital</s1><s2>London</s2><s3>GBR</s3><sZ>3 aut.</sZ></inist:fA14><country>Royaume-Uni</country></affiliation></author><author><name sortKey="Melamed, E" sort="Melamed, E" uniqKey="Melamed E" first="E." last="Melamed">E. Melamed</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Neurology, Rabin Medical Centre, Tel Aviv University, Sackler School of Medicine</s1><s2>Tel Aviv</s2><s3>ISR</s3><sZ>4 aut.</sZ></inist:fA14><country>Israël</country></affiliation></author><author><name sortKey="Oertel, W" sort="Oertel, W" uniqKey="Oertel W" first="W." last="Oertel">W. Oertel</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Philipps-University of Marburg, Centre of Nervous Diseases</s1><s2>Marburg</s2><s3>DEU</s3><sZ>5 aut.</sZ></inist:fA14><country>Allemagne</country></affiliation></author><author><name sortKey="Poewe, W" sort="Poewe, W" uniqKey="Poewe W" first="W." last="Poewe">W. Poewe</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Neurology, University of Innsbruck</s1><s2>Innsbruck</s2><s3>AUT</s3><sZ>6 aut.</sZ></inist:fA14><country>Autriche</country></affiliation></author><author><name sortKey="Stocchi, F" sort="Stocchi, F" uniqKey="Stocchi F" first="F." last="Stocchi">F. Stocchi</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Institute of Neurology, IRCCS Neuromed</s1><s2>Pozzilli</s2><s3>ITA</s3><sZ>7 aut.</sZ></inist:fA14><country>Italie</country></affiliation></author><author><name sortKey="Tolosa, E" sort="Tolosa, E" uniqKey="Tolosa E" first="E." last="Tolosa">E. Tolosa</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Neurology Service, Institut de Malalties del Sistema Nervios, Hospital Clinic, Institut d'lnvestigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona</s1><s2>Barcelona</s2><s3>ESP</s3><sZ>8 aut.</sZ></inist:fA14><country>Espagne</country></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">05-0151757</idno><date when="2005">2005</date><idno type="stanalyst">PASCAL 05-0151757 INIST</idno><idno type="RBID">Pascal:05-0151757</idno><idno type="wicri:Area/PascalFrancis/Corpus">000D09</idno><idno type="wicri:Area/PascalFrancis/Curation">000725</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study) : a randomised, double-blind, parallel-group trial. Commentary</title><author><name sortKey="Clarke, Carl E" sort="Clarke, Carl E" uniqKey="Clarke C" first="Carl E." last="Clarke">Carl E. Clarke</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>University of Birmingham and Department of Neurology, City Hospital</s1><s2>Birmingham B18 7QH</s2><s3>GBR</s3><sZ>1 aut.</sZ></inist:fA14><country>Royaume-Uni</country></affiliation></author><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O." last="Rascol">O. Rascol</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Clinical Pharmacology, University Hospital</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>2 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Brooks, D J" sort="Brooks, D J" uniqKey="Brooks D" first="D. J." last="Brooks">D. J. Brooks</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital</s1><s2>London</s2><s3>GBR</s3><sZ>3 aut.</sZ></inist:fA14><country>Royaume-Uni</country></affiliation></author><author><name sortKey="Melamed, E" sort="Melamed, E" uniqKey="Melamed E" first="E." last="Melamed">E. Melamed</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Neurology, Rabin Medical Centre, Tel Aviv University, Sackler School of Medicine</s1><s2>Tel Aviv</s2><s3>ISR</s3><sZ>4 aut.</sZ></inist:fA14><country>Israël</country></affiliation></author><author><name sortKey="Oertel, W" sort="Oertel, W" uniqKey="Oertel W" first="W." last="Oertel">W. Oertel</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Philipps-University of Marburg, Centre of Nervous Diseases</s1><s2>Marburg</s2><s3>DEU</s3><sZ>5 aut.</sZ></inist:fA14><country>Allemagne</country></affiliation></author><author><name sortKey="Poewe, W" sort="Poewe, W" uniqKey="Poewe W" first="W." last="Poewe">W. Poewe</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Neurology, University of Innsbruck</s1><s2>Innsbruck</s2><s3>AUT</s3><sZ>6 aut.</sZ></inist:fA14><country>Autriche</country></affiliation></author><author><name sortKey="Stocchi, F" sort="Stocchi, F" uniqKey="Stocchi F" first="F." last="Stocchi">F. Stocchi</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Institute of Neurology, IRCCS Neuromed</s1><s2>Pozzilli</s2><s3>ITA</s3><sZ>7 aut.</sZ></inist:fA14><country>Italie</country></affiliation></author><author><name sortKey="Tolosa, E" sort="Tolosa, E" uniqKey="Tolosa E" first="E." last="Tolosa">E. Tolosa</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Neurology Service, Institut de Malalties del Sistema Nervios, Hospital Clinic, Institut d'lnvestigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona</s1><s2>Barcelona</s2><s3>ESP</s3><sZ>8 aut.</sZ></inist:fA14><country>Espagne</country></affiliation></author></analytic><series><title level="j" type="main">Lancet : (British edition)</title><title level="j" type="abbreviated">Lancet : (Br. ed.)</title><idno type="ISSN">0140-6736</idno><imprint><date when="2005">2005</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Lancet : (British edition)</title><title level="j" type="abbreviated">Lancet : (Br. ed.)</title><idno type="ISSN">0140-6736</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson agent</term><term>Clinical trial</term><term>Critical study</term><term>Double blind study</term><term>Fluctuations</term><term>Human</term><term>Levodopa</term><term>Medicine</term><term>Parkinson disease</term><term>Rasagiline</term><term>Treatment</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Rasagiline</term><term>Lévodopa</term><term>Homme</term><term>Parkinson maladie</term><term>Fluctuation</term><term>Traitement</term><term>Etude double insu</term><term>Essai clinique</term><term>Etude critique</term><term>Médecine</term><term>Antiparkinsonien</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term><term>Médecine</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background Rasagiline mesylate is a novel drug for Parkinson's disease with selective, irreversible monoamine oxidase B (MAO-B) inhibitor activity, and is effective as monotherapy in early disease. This study investigated rasagiline efficacy and safety in levodopa-treated patients with Parkinson's disease and motor fluctuations. Methods In an 18-week, double-blind, multicentre (74 hospitals and academic centres in Israel, Argentina, and Europe) trial, 687 outpatients were randomly assigned to oral rasagiline (231 individuals; 1 mg once daily), entacapone (227; 200 mg with every levodopa dose), or placebo (229). Primary outcome was change in total daily off-time (intention-to-treat population). Other measures included the clinical global improvement (CGI) score and unified Parkinson's disease rating scale (UPDRS) scores. Analysis was by intention to treat. Findings 88 (13%) patients who were assigned treatment did not complete the study (23 rasagiline, 30 entacapone, 35 placebo), mainly because of withdrawal of consent (n=34) and adverse events (n=34). Both rasagiline and entacapone reduced mean daily off-time (-1.18 h rasagiline and -1.2 h entacapone vs placebo -0.4 h; p=0.0001, p<0.0001, respectively) and increased daily on-time without troublesome dyskinesia (0.85 h vs placebo 0.03 h; p=0.0005 for both). We recorded significant mean improvements in CGI scores (-0.86 rasagiline and -0.72 entacapone vs -0.37 placebo; p<0.0001, p=0.0002, respectively). Changes in UPDRS scores also significantly improved for activities of daily living during off-time (-1.71 and -1.38 vs placebo; p<0.0001, p=0.0006, respectively) and motor function during on-time (-2.94 and -2.73 vs placebo; both p<0.0001). Frequency of adverse events was similar for all treatments. Interpretation Once-daily rasagiline reduces mean daily off-time and improves symptoms of Parkinson's disease in levodopa-treated patients with motor fluctuations, an effect similar to that of entacapone.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0140-6736</s0></fA01><fA02 i1="01"><s0>LANCAO</s0></fA02><fA03 i2="1"><s0>Lancet : (Br. ed.)</s0></fA03><fA05><s2>365</s2></fA05><fA06><s2>9463</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study) : a randomised, double-blind, parallel-group trial. Commentary</s1></fA08><fA11 i1="01" i2="1"><s1>CLARKE (Carl E.)</s1><s9>comment.</s9></fA11><fA11 i1="02" i2="1"><s1>RASCOL (O.)</s1></fA11><fA11 i1="03" i2="1"><s1>BROOKS (D. J.)</s1></fA11><fA11 i1="04" i2="1"><s1>MELAMED (E.)</s1></fA11><fA11 i1="05" i2="1"><s1>OERTEL (W.)</s1></fA11><fA11 i1="06" i2="1"><s1>POEWE (W.)</s1></fA11><fA11 i1="07" i2="1"><s1>STOCCHI (F.)</s1></fA11><fA11 i1="08" i2="1"><s1>TOLOSA (E.)</s1></fA11><fA14 i1="01"><s1>University of Birmingham and Department of Neurology, City Hospital</s1><s2>Birmingham B18 7QH</s2><s3>GBR</s3><sZ>1 aut.</sZ></fA14><fA14 i1="02"><s1>Department of Clinical Pharmacology, University Hospital</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>2 aut.</sZ></fA14><fA14 i1="03"><s1>Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital</s1><s2>London</s2><s3>GBR</s3><sZ>3 aut.</sZ></fA14><fA14 i1="04"><s1>Department of Neurology, Rabin Medical Centre, Tel Aviv University, Sackler School of Medicine</s1><s2>Tel Aviv</s2><s3>ISR</s3><sZ>4 aut.</sZ></fA14><fA14 i1="05"><s1>Philipps-University of Marburg, Centre of Nervous Diseases</s1><s2>Marburg</s2><s3>DEU</s3><sZ>5 aut.</sZ></fA14><fA14 i1="06"><s1>Department of Neurology, University of Innsbruck</s1><s2>Innsbruck</s2><s3>AUT</s3><sZ>6 aut.</sZ></fA14><fA14 i1="07"><s1>Institute of Neurology, IRCCS Neuromed</s1><s2>Pozzilli</s2><s3>ITA</s3><sZ>7 aut.</sZ></fA14><fA14 i1="08"><s1>Neurology Service, Institut de Malalties del Sistema Nervios, Hospital Clinic, Institut d'lnvestigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona</s1><s2>Barcelona</s2><s3>ESP</s3><sZ>8 aut.</sZ></fA14><fA17 i1="01" i2="1"><s1>LARGO study group</s1><s3>INC</s3></fA17><fA20><s2>914-916,947-954 [11 p.]</s2></fA20><fA21><s1>2005</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>5004</s2><s5>354000126430530120</s5></fA43><fA44><s0>0000</s0><s1>© 2005 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>29 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>05-0151757</s0></fA47><fA60><s1>P</s1><s3>AR</s3><s3>CT</s3></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Lancet : (British edition)</s0></fA64><fA66 i1="01"><s0>GBR</s0></fA66><fC01 i1="01" l="ENG"><s0>Background Rasagiline mesylate is a novel drug for Parkinson's disease with selective, irreversible monoamine oxidase B (MAO-B) inhibitor activity, and is effective as monotherapy in early disease. This study investigated rasagiline efficacy and safety in levodopa-treated patients with Parkinson's disease and motor fluctuations. Methods In an 18-week, double-blind, multicentre (74 hospitals and academic centres in Israel, Argentina, and Europe) trial, 687 outpatients were randomly assigned to oral rasagiline (231 individuals; 1 mg once daily), entacapone (227; 200 mg with every levodopa dose), or placebo (229). Primary outcome was change in total daily off-time (intention-to-treat population). Other measures included the clinical global improvement (CGI) score and unified Parkinson's disease rating scale (UPDRS) scores. Analysis was by intention to treat. Findings 88 (13%) patients who were assigned treatment did not complete the study (23 rasagiline, 30 entacapone, 35 placebo), mainly because of withdrawal of consent (n=34) and adverse events (n=34). Both rasagiline and entacapone reduced mean daily off-time (-1.18 h rasagiline and -1.2 h entacapone vs placebo -0.4 h; p=0.0001, p<0.0001, respectively) and increased daily on-time without troublesome dyskinesia (0.85 h vs placebo 0.03 h; p=0.0005 for both). We recorded significant mean improvements in CGI scores (-0.86 rasagiline and -0.72 entacapone vs -0.37 placebo; p<0.0001, p=0.0002, respectively). Changes in UPDRS scores also significantly improved for activities of daily living during off-time (-1.71 and -1.38 vs placebo; p<0.0001, p=0.0006, respectively) and motor function during on-time (-2.94 and -2.73 vs placebo; both p<0.0001). Frequency of adverse events was similar for all treatments. Interpretation Once-daily rasagiline reduces mean daily off-time and improves symptoms of Parkinson's disease in levodopa-treated patients with motor fluctuations, an effect similar to that of entacapone.</s0></fC01><fC02 i1="01" i2="X"><s0>002B01</s0></fC02><fC02 i1="02" i2="X"><s0>002B17G</s0></fC02><fC02 i1="03" i2="X"><s0>002B17A01</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Rasagiline</s0><s2>NK</s2><s2>FR</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Rasagiline</s0><s2>NK</s2><s2>FR</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Rasagilina</s0><s2>NK</s2><s2>FR</s2><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Lévodopa</s0><s2>NK</s2><s2>FR</s2><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Levodopa</s0><s2>NK</s2><s2>FR</s2><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Levodopa</s0><s2>NK</s2><s2>FR</s2><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Homme</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Human</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Hombre</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Parkinson maladie</s0><s5>04</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Parkinson disease</s0><s5>04</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Parkinson enfermedad</s0><s5>04</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Fluctuation</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Fluctuations</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Fluctuación</s0><s5>05</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Traitement</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Treatment</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Tratamiento</s0><s5>06</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Etude double insu</s0><s5>08</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Double blind study</s0><s5>08</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Estudio doble ciego</s0><s5>08</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Essai clinique</s0><s5>09</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Clinical trial</s0><s5>09</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Ensayo clínico</s0><s5>09</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Etude critique</s0><s5>11</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Critical study</s0><s5>11</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Estudio crítico</s0><s5>11</s5></fC03><fC03 i1="10" i2="X" l="FRE"><s0>Médecine</s0><s5>12</s5></fC03><fC03 i1="10" i2="X" l="ENG"><s0>Medicine</s0><s5>12</s5></fC03><fC03 i1="10" i2="X" l="SPA"><s0>Medicina</s0><s5>12</s5></fC03><fC03 i1="11" i2="X" l="FRE"><s0>Antiparkinsonien</s0><s5>25</s5></fC03><fC03 i1="11" i2="X" l="ENG"><s0>Antiparkinson agent</s0><s5>25</s5></fC03><fC03 i1="11" i2="X" l="SPA"><s0>Antiparkinsoniano</s0><s5>25</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Agoniste</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Agonist</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Agonista</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Récepteur dopaminergique D2</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>D2 Dopamine receptor</s0><s5>38</s5><s6>«D2» Dopamine receptor</s6></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Receptor dopaminérgico D2</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0><s5>39</s5></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0><s5>40</s5></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0><s5>41</s5></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0><s5>41</s5></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0><s5>41</s5></fC07><fC07 i1="06" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0><s5>42</s5></fC07><fC07 i1="06" i2="X" l="ENG"><s0>Central nervous system disease</s0><s5>42</s5></fC07><fC07 i1="06" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0><s5>42</s5></fC07><fC07 i1="07" i2="X" l="FRE"><s0>Système nerveux pathologie</s0><s5>43</s5></fC07><fC07 i1="07" i2="X" l="ENG"><s0>Nervous system diseases</s0><s5>43</s5></fC07><fC07 i1="07" i2="X" l="SPA"><s0>Sistema nervioso patología</s0><s5>43</s5></fC07><fN21><s1>101</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000725 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000725 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PascalFrancis
|étape= Curation
|type= RBID
|clé= Pascal:05-0151757
|texte= Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study) : a randomised, double-blind, parallel-group trial. Commentary
}}
| This area was generated with Dilib version V0.6.29. |  |